Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis

Cancer Prevention Research

Volumn 3, Issue 3, 2010, Pages 348-358

  Davids, Jennifer S ^a   Carothers, Adelaide M ^a   Damas, Beatrice C ^a   Bertagnolli, Monica M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD34 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FIBRONECTIN; HEPARANASE; PROSTAGLANDIN E2; SYNDECAN 1; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BONE MARROW; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; INTESTINAL FIBROSIS; LAMINA PROPRIA; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; STROMA;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; FIBROSIS; GENES, APC; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; INTESTINAL NEOPLASMS; INTESTINES; MICE; MICE, INBRED C57BL; POLYSACCHARIDE-LYASES; PYRAZOLES; SIGNAL TRANSDUCTION; STROMAL CELLS; SULFONAMIDES; SYNDECAN-1; TRANSFORMING GROWTH FACTOR BETA;

EID: 77949765687     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0146     Document Type: Article

References (42)

1. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
2. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
3. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355: 885-95.
4. Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol 2007;8:439-43.
5. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
6. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
7. Carothers AM, Moran AE, Cho NL, Redston M, Bertagnolli MM. Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2-inhibitor. Cancer Res 2006;66:6432-8.
8. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (△716) knockout mice. Nat Med 2001;7:1048-51.
9. Powell DW, Adegboyege PA, Di Mari JF, Mifflin RC. Epthelial cells and their neighbors: I. Role of intestinal myofibroblasts in development, repair, and cancer. Am J Physiol 2005;289:G2-7.
10. Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses. Gastroenterology 2003;124:1866-78.
11. Takeda H, Miyoshi H, Tamai Y, Oshima M, Taketo MM. Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas. Br J Cancer 2004;90:701-4.
12. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;493-501.
13. Enders G. Cyclooxygenase 2 overexpression abrogates the antiproliferative effects of TGF-β. Br J Cancer 2007;7:1388-92.
14. Pardali K, Moustakas A. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007; 1775:21-62.
15. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFβ activation. J Cell Sci 2003;116:217-24.
16. Zhu Y, Richardson J, Parada L, Graff J. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998;703-14.
17. Becker C, Fantini M, Neurath M. TGF-β as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev 2006;17: 97-106.
18. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodeling. Nat Rev Mol Cell Biol 2002;3:349-63.
19. Grady W, Rajput A, Meyeroff L, et al. Mutation of the type II transforming growth factor β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998;58:3101-4.
20. McKaig BC, Hughes K, Tighe PJ, Mahida TR. Differential expression of TGFβ isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol 2002;C172-82.
21. Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor-β signaling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009;58:777-89.
22. Saisekharan R, Shriver Z, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521-8.
23. Hashimoto Y, Skacel M, Adams JC. Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 2008;8:185.
24. Alexander CM, Reichsman F, Hinkes MT, et al. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 2000;25:329-32.
25. Chen Q, Sivakumar P, Barley C, Peters DM, Gomes RR, Farach-Carson MC. Potential role of heparan sulfate proteoglycans in regulation of transforming growth factor-β (TGF-β) bymodulating assembly of latent TGF-β-binding protein-1. J Biol Chem 2007;282:26418-30.
26. Bode L, Salvestrini C, Park PW, et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 2008;118:229-38.
27. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. Shedding of syndecan-1 and -1 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000;148:811-24.
28. Kliment CR, Englert JM, Gouchuico BR, et al. Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J Biol Chem 2009;284:3537-45.
29. Yang Y, MacLeod V, Miao H-Q, et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007;282:13326-33.
30. Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, Ilan N. Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 2007;20:8-14.
31. Carothers AM, Melstrom KAJ, Mueller JD, Weyant MJ, Bertagnolli MM. Progressive changes in adherens junction structure during intestinal adenoma formation in Apc mutant mice. J Biol Chem 2001; 276:39094-102.
32. Bellin A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007;87:858-70.
33. Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinoma. Cancer Res 1995;55:4132-9.
34. Bertagnolli MM, Eagle CJ, Zauber AG, et al. A randomized trial of celecoxib to prevent sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
35. Cho NL, Zauber A, Redston M, et al. Aberrant crypt foci in the Adenoma Prevention with Celecoxib (APC) Trial. Cancer Prev Res 2008;1:21-31.
36. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 stimulates the β-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 2005;280:26565-72.
37. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 2004;43261-72.
38. Vaahtomeri K, Ventelä E, Laajanen K, et al. Lkb1 is required for TGFβ-mediated myofibroblast differentiation. J Cell Sci 2008;121: 3531-40.
39. Shim J-H, Xiao C, Paschal AE, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005;19:2668-81.
40. Lu T, Tian L, Han Y, Vogelbaum M, Stark GR. Dose-dependent crosstalk between the transforming growth factor-β and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A 2007;104:4365-70.
41. Greten FR, Arkan MC, Bollrath J, et al. NF-κβ is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 2007;130:918-31.
42. Moran AE, Carothers AM, Weyant MJ, Redston M, Bertagnolli MM. Carnosol inhibits β-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J-Min/+ (Min/+) mouse. Cancer Res 2005;65:1097-104.